Perfecseal Introduces New Packaging Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Perfecseal Introduces New Packaging Products
Perfecseal's high-barrier PVC-free blister-forming web, PerfecForm SkyBlue, is based on polyolefin chemistry, and its new high-barrier flow-wrap specification, PerfecPharm P232, is capable of achieving hermetic seals at the maximum speed capabilities of the top flow-wrap equipment.


Perfecseal has introduced a new high-barrier, PVC-free, blister-forming web, PerfecForm SkyBlue, designed to be cost effective and provide barrier properties to protect all but the highest barrier requirement product applications. This high-barrier blister film is based on polyolefin chemistry, rather than the chlorine chemistry used to produce PVC forming webs.

Unlike other barrier blister films, PerfecForm SkyBlue is manufactured via a co-extrusion process as a symmetrical structure. The thickness of the barrier layer, which is sandwiched between co-polyester, determines the overall barrier performance.

Perfecseal has also introduced a new high-barrier flow-wrap specification, PerfecPharm P232, which is capable of achieving hermetic seals at the maximum speed capabilities of the top flow-wrap equipment. “Perfecseal evaluated this product on high-speed Bosch flow-wrap equipment to assure this product would meet the desired performance level demanded by the healthcare market,” states Georgia Mohr, pharmaceutical director of Perfecseal, in a press release. “The P232 flow wrap material offers a large sealing window (140°C–200°C) and the potential to run at lower temperatures than traditional materials, yet seals hermetically at speeds exceeding 300 ppm.” Once again, Perfecseal delivers packaging solutions based on material science expertise.

Perfecseal, a division of Bemis Company, specializes in healthcare packaging and delivers packaging solutions based on material science expertise.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here